JP2014508138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508138A5 JP2014508138A5 JP2013549850A JP2013549850A JP2014508138A5 JP 2014508138 A5 JP2014508138 A5 JP 2014508138A5 JP 2013549850 A JP2013549850 A JP 2013549850A JP 2013549850 A JP2013549850 A JP 2013549850A JP 2014508138 A5 JP2014508138 A5 JP 2014508138A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- combination
- group
- heparin
- thrombin inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11152119 | 2011-01-25 | ||
| EP11152119.1 | 2011-01-25 | ||
| PCT/EP2012/051157 WO2012101181A1 (en) | 2011-01-25 | 2012-01-25 | Compositions and methods for cell transplantation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508138A JP2014508138A (ja) | 2014-04-03 |
| JP2014508138A5 true JP2014508138A5 (enExample) | 2015-03-12 |
| JP6012629B2 JP6012629B2 (ja) | 2016-10-25 |
Family
ID=45607724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549850A Expired - Fee Related JP6012629B2 (ja) | 2011-01-25 | 2012-01-25 | 細胞移植のための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20130302291A1 (enExample) |
| EP (1) | EP2667878B1 (enExample) |
| JP (1) | JP6012629B2 (enExample) |
| CN (1) | CN103402527B (enExample) |
| CA (1) | CA2825252C (enExample) |
| DK (1) | DK2667878T3 (enExample) |
| ES (1) | ES2573522T3 (enExample) |
| IL (1) | IL227529A0 (enExample) |
| PL (1) | PL2667878T3 (enExample) |
| PT (1) | PT2667878E (enExample) |
| SG (1) | SG192124A1 (enExample) |
| WO (1) | WO2012101181A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2667878B1 (en) | 2011-01-25 | 2016-03-30 | Université Catholique de Louvain | Compositions and methods for cell transplantation |
| US9775890B2 (en) | 2012-01-25 | 2017-10-03 | Université Catholique de Louvain | Factor Xa inhibitor used with liver-derived progenitor cells |
| EP2943206A4 (en) * | 2013-01-12 | 2017-01-04 | Cesca Therapeutics Inc. | Rapid infusion of autologous bone marrow derived stem cells |
| MX376437B (es) * | 2013-03-15 | 2025-03-04 | Miromatrix Medical Inc | Uso de hígado descelularizado por perfusión para recelularización de células de islote. |
| EP3016665B1 (en) | 2013-07-05 | 2019-09-18 | Université Catholique de Louvain | Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders |
| BR102013033827B1 (pt) * | 2013-12-27 | 2021-09-08 | Regenera - Medicina Veterinária Avançada Ltda. | Concentrado multipotente e imunocompatível de células-tronco e biofármaco e forma de dosagem que o compreendem |
| CN108367023B (zh) * | 2015-06-11 | 2021-04-20 | 马斯特里赫特大学 | 预防宿主中移植物衰竭的方法 |
| CN106995796A (zh) * | 2016-01-26 | 2017-08-01 | 李建业 | 基于细胞因子的细胞处理方法、试剂盒及冻干粉 |
| CN116590227A (zh) | 2017-03-03 | 2023-08-15 | 日本乐敦制药株式会社 | 间充质干细胞和肝疾病治疗剂 |
| TW201902467A (zh) * | 2017-06-12 | 2019-01-16 | 北卡羅來納大學教堂山 | 用於細胞植入的補釘移植物組成物 |
| JP7264589B2 (ja) * | 2017-12-25 | 2023-04-25 | 株式会社 資生堂 | トロンビンの抑制作用を指標とした皮膚状態改善剤のスクリーニング方法、及びトロンビン作用阻害剤を含む皮膚状態改善剤 |
| WO2019241499A1 (en) | 2018-06-13 | 2019-12-19 | Miromatrix Medical Inc. | Fistula filler and deployment system |
| CN113677790B (zh) * | 2019-03-26 | 2024-05-24 | 普罗米瑟拉疗法公司 | 用于治疗慢加急性肝衰竭的成体肝祖细胞 |
| CN112608890B (zh) * | 2020-12-17 | 2024-08-20 | 山东佰鸿干细胞生物技术有限公司 | 一种防止间充质干细胞粘连的培养方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9010552D0 (en) | 1990-05-10 | 1990-07-04 | Erba Carlo Spa | Method for the recombinant production of hirudins and novel hirudins |
| US5837539A (en) | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
| US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
| US5827740A (en) | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
| GB0014136D0 (en) | 2000-06-10 | 2000-08-02 | Astrazeneca Ab | Combination therapy |
| DE10202982A1 (de) | 2002-01-26 | 2003-07-31 | Augustinus Bader | Verfahren und Vorrichtung zum Einbringen von lebenden Zellen in eine biologische Körperflüssigkeit |
| US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
| WO2006126219A1 (en) | 2005-05-26 | 2006-11-30 | Fresenius Medical Care Deutschland G.M.B.H. | Liver progenitor cells |
| AU2006292203A1 (en) | 2005-09-21 | 2007-03-29 | Dask Technologies, Llc | Methods and compositions for organ and tissue functionality |
| ATE498005T1 (de) | 2005-12-21 | 2011-02-15 | Univ Catholique Louvain | Isolierte leberstammzellen |
| EP2667878B1 (en) | 2011-01-25 | 2016-03-30 | Université Catholique de Louvain | Compositions and methods for cell transplantation |
| US9775890B2 (en) | 2012-01-25 | 2017-10-03 | Université Catholique de Louvain | Factor Xa inhibitor used with liver-derived progenitor cells |
-
2012
- 2012-01-25 EP EP12704242.2A patent/EP2667878B1/en not_active Not-in-force
- 2012-01-25 CN CN201280011169.6A patent/CN103402527B/zh not_active Expired - Fee Related
- 2012-01-25 WO PCT/EP2012/051157 patent/WO2012101181A1/en not_active Ceased
- 2012-01-25 JP JP2013549850A patent/JP6012629B2/ja not_active Expired - Fee Related
- 2012-01-25 SG SG2013056510A patent/SG192124A1/en unknown
- 2012-01-25 DK DK12704242.2T patent/DK2667878T3/en active
- 2012-01-25 CA CA2825252A patent/CA2825252C/en not_active Expired - Fee Related
- 2012-01-25 PL PL12704242.2T patent/PL2667878T3/pl unknown
- 2012-01-25 ES ES12704242.2T patent/ES2573522T3/es active Active
- 2012-01-25 PT PT127042422T patent/PT2667878E/pt unknown
- 2012-01-25 US US13/981,720 patent/US20130302291A1/en not_active Abandoned
-
2013
- 2013-07-18 IL IL227529A patent/IL227529A0/en active IP Right Grant
-
2016
- 2016-10-06 US US15/287,061 patent/US10039789B2/en not_active Expired - Fee Related
-
2017
- 2017-08-25 US US15/687,340 patent/US10478459B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508138A5 (enExample) | ||
| JP2015508054A5 (enExample) | ||
| Sang et al. | Intraportal mesenchymal stem cell transplantation prevents acute liver failure through promoting cell proliferation and inhibiting apoptosis | |
| WO2009033731A3 (en) | Use of a laminin peptide as a therapeutic agent | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| WO2009043464A3 (en) | Astressin and beta- endorphin for use as therapeutic agents | |
| Slegtenhorst et al. | Mechanisms and consequences of injury and repair in older organ transplants | |
| WO2009033733A3 (en) | Use of apeptide as a therapeutic agent | |
| WO2009033678A3 (en) | Use of a tuftsin as a therapeutic agent | |
| WO2009033756A3 (en) | Use of oxyntomodulin alone or in combination with melanotropin potentiating factor as a therapeutic agent | |
| WO2009033717A3 (en) | Use of gonadorelin as a therapeutic agent | |
| WO2009033789A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009040046A3 (en) | Use of stresscopin-related peptide as a therapeutic agent | |
| WO2009040048A3 (en) | Use of the c-reactive peptide as a therapeutic agent | |
| WO2009033760A3 (en) | Use of fibronectin fragment (196-203 ) as a therapeutic agent | |
| JP2015510393A5 (enExample) | ||
| WO2009040028A3 (en) | Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis | |
| Tombor et al. | Why is endothelial resilience key to maintain cardiac health? | |
| NZ718514A (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| WO2009043449A3 (en) | Use of a peptide as a therapeutic agent | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| Yamaguchi et al. | Diverse functions of the thrombopoietin receptor agonist romiplostim rescue individuals exposed to lethal radiation | |
| Chen et al. | Exosomes derived from human umbilical cord mesenchymal stem cells protect against papain-induced emphysema by preventing apoptosis through activating VEGF-VEGFR2-mediated AKT and MEK/ERK pathways in rats | |
| WO2009040033A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009046860A3 (en) | Use of dago as a therapeutic agent |